Juul submits the first PMTA for its next-generation vapour platform

Juul Labs has submitted a premarket tobacco product application (PMTA) for the company’s next-generation vapour platform to the US Food and Drug Administration (FDA).

The PMTA includes new evidence from the UK on how the device can aid smoking cessation, as well as data and specifications around preventing youth usage of the device, which will use only new tobacco-flavoured pods at 18 mg/ml nicotine concentration.


Benefits of subscription plans:

  • Stay informed of any legal and market change in the sector that impacts your organization
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Need help?

Contact a sales representative right now and don’t wait

Email us